Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY – Get Free Report) was the target of a large decline in short interest during the month of July. As of July 15th, there was short interest totaling 200 shares, a decline of 97.2% from the June 30th total of 7,045 shares. Based on an average daily trading volume, of 3,664 shares, the days-to-cover ratio is currently 0.1 days.
Clinuvel Pharmaceuticals Price Performance
Shares of Clinuvel Pharmaceuticals stock remained flat at $7.35 on Friday. 36,763 shares of the company traded hands, compared to its average volume of 3,028. Clinuvel Pharmaceuticals has a 1-year low of $5.98 and a 1-year high of $9.00. The business has a 50-day moving average of $6.95 and a two-hundred day moving average of $7.22.
About Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company headquartered in Melbourne, specializing in the development and commercialisation of photoprotective and phototherapeutic solutions. The company’s research centers on harnessing the skin’s natural photoprotective pathways by modulating the melanocortin system, with a view to addressing a range of skin disorders and conditions that are exacerbated by ultraviolet light exposure.
The company’s flagship product, Scenesse (afamelanotide), is the first systemic photoprotective drug approved by both the European Medicines Agency and the U.S.
Featured Stories
- Five stocks we like better than Clinuvel Pharmaceuticals
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
- Plugging In: How Kinder Morgan Powers Up Profits
Receive News & Ratings for Clinuvel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinuvel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
